Sign In
Buy NVO
$47.42
+1.52 (+3.31%)
At Close: Jun 23, 2026
Is This Deal a Game Changer for Novo Nordisk?
08:30pm, Monday, 27'th Apr 2026
The drugmaker is getting on the AI train in ways that could move the needle down the road.
Novo Nordisk vs. Pfizer: Which Healthcare Giant Is the Better Bet?
11:21am, Monday, 27'th Apr 2026
NVO and PFE clash as the obesity market heats up, with shifting strategies, pipeline bets and growth pressures reshaping their investment outlook.
GLP-1 pill race heats up as Wegovy tablet holds strong against Lilly rival
11:02am, Monday, 27'th Apr 2026
Novo Nordisk's (NYSE:NVO) Wegovy pill, the oral version of its blockbuster GLP-1 (glucagon-like peptide-1) weight-loss treatment, is tracking at roughly...
GLP-1 pill race heats up as Wegovy tablet holds strong against Lilly rival
10:15am, Monday, 27'th Apr 2026
Novo Nordisk's (NYSE:NVO) Wegovy pill, the oral version of its blockbuster GLP-1 (glucagon-like peptide-1) weight-loss treatment, is tracking at roughly twice the prescription volumes of Eli Lilly's c
Is NVO Undervalued? DCF Says Worth $88
07:27am, Monday, 27'th Apr 2026
On April 27, 2026, we delve into the DCF analysis for Novo Nordisk AS (NVO), a company currently facing significant price fluctuations. Over the past year, NVO
Concurrent Investment Advisors LLC Increases Stock Holdings in Novo Nordisk A/S $NVO
05:16am, Monday, 27'th Apr 2026
Concurrent Investment Advisors LLC grew its position in Novo Nordisk A/S (NYSE: NVO) by 84.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and
Novo Nordisk A/S - share repurchase programme
04:56am, Monday, 27'th Apr 2026
Bagsværd, Denmark, 27 April 2026 – On 4 February 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Coun
Lilly stock falls as Foundayo trails Novo's Wegovy in early uptake
02:18pm, Friday, 24'th Apr 2026
Shares of Eli Lilly came under pressure on Friday after early prescription data for its newly launched weight-loss pill suggested a slower rollout compared with rival Novo Nordisk's competing product.
NVO Reports Strong Phase III Diabetes Data for Children & Adolescents
01:45pm, Friday, 24'th Apr 2026
Novo Nordisk reports phase III teen study success for oral semaglutide, showing strong HbA1c reduction and paving the way for the first oral GLP-1 for youth.
Depressed Equities That May Be Worth Investigating Further
12:29pm, Friday, 24'th Apr 2026
I highlight several companies—PYPL, LULU, and NVO—experiencing significant selloffs, potentially offering attractive valuations. Current investor sentiment is extremely negative, and momentum rema
Novo Nordisk Shares Rise After Positive Oral Semaglutide Trial In Children
09:32am, Friday, 24'th Apr 2026
Novo Nordisk A/S (NYSE:NVO) shares are trading higher Friday after the company announced results of an oral semaglutide trial in children aged 10-17 years old with type 2 diabetes.
Here's Why Agios Pharmaceuticals Stock Slumped This Week (And What Investors Have to Look Forward to in 2026)
05:36am, Friday, 24'th Apr 2026
A rival company's trial results had a negative impact on Agios' stock this week.
Novo Nordisk (NVO) Sees a More Significant Dip Than Broader Market: Some Facts to Know
06:46pm, Thursday, 23'rd Apr 2026
In the most recent trading session, Novo Nordisk (NVO) closed at $38.52, indicating a -1.61% shift from the previous trading day.
Novo Nordisk Advances Ozempic Pill for Kids
10:01am, Thursday, 23'rd Apr 2026
Novo Nordisk (NVO, Financials) announced it will introduce an oral version of Ozempic in the U.S. after the drug fulfilled its primary target in a late-stage tr
Is Novo Nordisk's 72% Crash a Generational Buying Opportunity or a Value Trap?
09:30am, Thursday, 23'rd Apr 2026
Novo Nordisk stock has been stuck in a downward spiral for quite some time.
